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INTRODUCTION
Adjuvants are critical components of most clinical vaccines and are used to enhance adaptive immune responses to antigen (1) . Adjuvants can help shape the quantity and quality of immune responses (1) . However, currently available FDA-licensed adjuvants are poor inducers of CD4 + T helper 1 (Th1) and even worse at treating CD8 + T cell responses (2, 3) . It is important to identify a new generation of potent vaccine adjuvant(s) that can drive and specifically direct both these desired responses. Thus, the inclusion of different molecular adjuvants, such as cytokines, are actively being studied as a way to increase the efficacy of vaccines. Different vaccine platforms have been studied, but the development of DNA-based vaccines in conjunction with cytokine adjuvants, has emerged as a particularly promising for inducing antiviral and anti-tumor cell-mediated immune responses (4, 5) . Indeed, the potency of DNA-based vaccines co-administered with molecular cytokine adjuvants as part of a vaccine cocktail has been demonstrated to boost the adaptive immune response (5) . Recently IL-12 as a vaccine molecular adjuvant has been shown to augment the T cell immunity induced by a DNA vaccine in humans (4) . IL-12 was particularly effective in expanding CD4 and CD8 immunity but less effective, in driving strong B cell immunity. Building on this important recent success is an area of great importance. We therefore employed a DNA vaccination approach to investigate the inclusion of Interleukin 33 (IL-33) to further enhance, both arms of the adaptive immune responses.
IL-33 is a member of the IL-1 family of cytokines that is constitutively expressed in the nucleus of epithelial and endothelial cells (6, 7) . IL-33 is classified as an alarmin-like molecule, whose release during cell injury signals tissue damage to local immune cells (7) . Alarmin IL-33 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 21, 2014; DOI: 10.1158/0008-5472.CAN- has been shown to have pleiotropic cytokine activities such as mediating diverse proinflammatory responses (9, 10) , activation and recruitment of antigen-presenting cells (11) , enhancing adaptive immunity (12, 13) , and wound healing (14) . To date, IL-33 has been studied primarily in the context of T helper type 2 (Th2) immune responses associated with modulating inflammatory disorders such as asthma and atopic dermatitis (6, 15, (16) (17) (18) and mature IL-33 (mtrIL-33) (18) . ProIL-33 is thought to be the most biologically active form promoting inflammation, while the function of mtrIL-33 in modulating immune responses remains more elusive (7, 15, 18) . Therefore, we investigated whether the two isoforms of IL-33 (proIL-33 and mtrIL-33) can function as vaccine adjuvants to augment both Th1 and CD8 + T cell responses and induce anti-tumor immunity using a murine model for HPV-associated cancer.
In this study, we demonstrate that IL-33 can act as a potent cell-mediated adjuvant using the DNA vaccine platform. Its adjuvant activity skews towards the Th1 axis, and not to the Th2 axis. We show that IL-33 can be effective as an adjuvant in either form -its uncleaved "pro" form or its "mature" state, a shorter form that results from cleavage by cellular enzymes (10, 17, 19 
Materials and Methods

Plasmid Construction
The GenBank sequence NM_001164724.1 for mouse IL-33 was used to synthesize full-length (proIL-33) and mature IL-33 (mtrIL-33) (aa 109-266) plasmid DNA constructs. Each construct had highly efficient immunoglobulin E (IgE) leader sequence inserted at the 5'end of the gene.
The constructs were commercially synthesized and optimized as described previously (20) .
Plasmid expressing HPV 16 ConE6E7 was prepared as previously described (21) . The GP33 construct was provided by Dr. Rafi Ahmed of Emory University, Atlanta GA, USA and used as described (22) .
Transfection and Expression of Plasmids
ProIL-33 and mtrIL-33 construct expression was confirmed using Western Blot and
Immunofluorescence microscopy in RD cells. (Supplementary Materials and Methods).
Animals
Female 8-week-old C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The P14 mice bearing the D b GP33-specific T-cell receptor were a kind gift from Dr. John 
Immunization/EP of mice
Mice were immunized three times at three-week intervals in the tibialis anterior muscle. In vivo Electroporation (EP) was delivered, with the CELLECTRA adaptive constant current EP device (Inovio Pharmaceuticals, Blue Bell, PA), at the same site immediately following vaccination as described (20) . The mice (n=4-5) were immunized with either 5μg pVAX1 or 5μg ConE6E7 alone or with various amounts of proIL-33 and mtrIL-33 constructs, depending on the experiment. The GP33 construct was administered at 5μg. All studies were repeated twice.
ELISpot assays
Spleens were harvested 8 days following the final immunization as previously described (20) .
After spleens were harvested and processed both IFN-γ and IL-4 ELISpot assays were performed to determine antigen-specific cytokine secretion from immunized mice as described previously (20, 21, 22) .
Flow Cytometry
Lymphocytes were isolated and processed from the spleen and peripheral blood as previously described (20, 23, 24) . The antibodies used in the present study are listed in the Supplementary Materials and Methods. Tumor Cell line TC-1 cells were purchased from ATCC and cultured as previously described (25) . The TC-1 cell line was a graciously given gift from Dr. Yvonne Paterson of the University of Pennsylvania, Philadelphia, PA, USA. The TC-1 cell line is well-characterized, constitutively expresses E6 and E7, and is highly tumorigenic (25, 26) . TC-1 cells were prepared and mixed with Matrigel (BD Bioscience) for subcutaneous (s.c.) tumor implantation.
In vivo tumor treatment (regression) study
Female B6 mice were separated into four groups of 10 mice each and 5 x 10 
Statistical analysis
Student's t-test was applied for comparison of the quantitative data of the cellular immune response and tumor diameters. Error bars indicate SEM and all tests were performed using Prism Software (***P < 0.001, **P < 0.01, *P < 0.05 compared with ConE6E7). 
RESULTS
Construction and expression of IL-33 isoforms
Two IL-33 adjuvants constructs (pro-IL33 and mtrIL-33) were designed and generated to test our working hypothesis (Fig. 1A) . To determine the expression of both IL-33 isoforms, human rhabdomyosarcoma (RD) cells were transfected separately with each construct, and expression was assessed by Western immunoblotting. A ~20kDA protein was observed for mtrIL-33 and a ~30kDA and ~20kDA protein size was observed for proIL-33, in cell lyates harvested 48 hours after transfection using an anti-IL33 monoclonal antibody (mAb) for detection (Fig. 1B) . For a comparative control, no protein band could be detected in the negative pVAX control. To examine the cytokine secretion of both isoforms, cell supernatants were obtained 48 hours after transfection in RD cells and the detection of cytokine secretion into the extracellular environment were carried out by enzyme-linked immunosorbent assays (ELISAs).
As shown in Fig. 1C , supernatants from mtrIL-33 and proIL-33 transfected RD cells contained mtrIL-33 and proIL-33 at concentrations of roughly 20,000 pg/ml and 600 pg/ml, respectively. Finally, the expression for both IL-33 isoforms was further confirmed using immunoflourescent staining using an anti-IL33 mAb. ProIL-33 can act both as a secreted cytokine and as a nuclear binding factor (19) . ProIL-33 nuclear localization is mediated by the nuclear localization signal in its N-terminus, which also contains a chromatin-binding motif (Fig. 1A) . However, the cleavage of proIL-33 into mtrIL-33 yields a truncated IL-33 that lacks the nuclear localization signal found in proIL-33. As projected, high nuclear expression with some cytoplasmic expression was observed in the proIL-33 transfected cells (Fig. 1D, bottom) . This is an important observation which supports previous findings showing that proIL-33 cytokine can also be expressed and found in the cytoplasm (27) . In contrast, only high cytoplasmic expression was visualized in the mtrIL-33 transfected cells shown in Fig. 1D , middle.
IL-33 adjuvant isoforms enhance potent HPV16 E6/E7-specific cellular immune responses following vaccination
A quantitative ELISpot assay was used to determine the number of antigen-specific IFN-γ secreting cells in response to stimulation with the E6 and E7 peptide pool. As we have reported, electroporation (EP) improves the immunogenicity or potency of DNA vaccines by increasing antigen expression (28, 29) , thus we performed ConE6E7/EP intramuscular (i.m.) vaccination in C57BL/6 (B6) mice (n=5) with a dosage of 5μg alone or in combination with either mtrIL-33 or proIL-33 at various doses followed by EP. One week after final immunization we monitored the degree of immune responses by isolating splenocytes for further analysis ( 4.9%), compared to mice that received the ConE6E7 constructs alone (Fig. 4E ). More interestingly, the HPV-adjuvanted vaccines elicited substantially higher frequencies of plurifunctional effector CD8 + T cells co-expressing CD107a/IFN-γ/TNF-α (mtrIL-33: 2.5%; proIL-33: 2.5%), compared to the ConE6E7 construct alone (Fig. 4F) . These results indicate the adjuvant potential of IL-33 to induce functional effector cytotoxic CTLs, which have a phenotype suggesting the cells ability to clear HPV16 infected cells.
IL-33 role in the induction of humoral responses
Identifying potent adjuvants that not only mediate protective cell-mediated immune responses, but can also induce humoral immune responses, will be ideal for enhancing effective 
difficulties curing in a tumor therapy study, however the inclusion of IL-33 makes a substantial difference (Fig. 6B) . Thus, our data illustrates that HPV-specific T cell immunity induced by both immunoadjuvants provides substantial protective anti-tumor immunity by further delaying or rapidly inducing complete regression of established TC-1 tumors. (Fig. 7) . As shown in Fig. 7A and Supplementary Fig. 2 , the GP33-proIL-33 adjuvanted group dramatically increased the frequency of P14 CD8 
IL-33 adjuvant expands
Discussion
In this study, we provide insight on the Th1-and CD8-biased adjuvant activity of two isoforms of IL-33-encoding plasmids in a DNA vaccine setting. We demonstrate that IL-33 elicits bonafide Ag-specific Th-1 cell-mediated immune responses to a consensus HPV16 E6/E7
antigen, but not IL-4, nor any elevation of IgE levels as previously described. Clearly both isoforms elicited strong HPV16 Ag-specific polyfunctional CD4 (Fig. 6) . Moreover, as shown in Fig. 7 , the peak of CD8 expansion (14 dpv) seemed to correlate with the complete tumor regression mediated by prolL-33, which was 17 days post first vaccination (Fig. 6B) . 
